Home The Word Brain	My Amedeo FAQ Privacy About
	C49 In our changing world, speaking just English isn't enough. Open new doors with skills in another world language. Start with 7 words a day. Next week: +49.

Lung Cancer

Free Subscription Articles published in Anticancer Res Retrieve available abstracts of 111 articles: HTML format

Single Articles

May 2025
1. HWANG HH, Yoo JS, Je JH, Lee HC, et al
   SH003 Inhibits Proliferation and Induces Apoptosis in NSCLC Cell Lines by Inhibiting the Receptor Tyrosine Kinase-related Pathway.
   Anticancer Res. 2025;45:1981-1995.
   PubMed     Abstract available
   
   
   
2. PROBST E, Idel C, Fleckner J, Plotze-Martin K, et al
   Elevated PD-L1 Expression on Circulating Classical Monocytes Upon Checkpoint Inhibitor Therapy Is Associated With Increased Plasma Interleukin 5 in Patients With Lung Cancer.
   Anticancer Res. 2025;45:1915-1925.
   PubMed     Abstract available
   
   
   
3. ASANO Y, Han Q, Mizuta K, Kang BM, et al
   Recombinant Methioninase and Cisplatinum Act Synergistically to Inhibit Lewis Lung Carcinoma Cells But Not Normal Fibroblasts.
   Anticancer Res. 2025;45:1871-1876.
   PubMed     Abstract available
   
   
   
4. DICKE J, Hero L, Kuhl S, Goldbrunner R, et al
   Expression of YAP1 and TAZ in Melanoma-, Bronchial- and Breast Carcinoma Brain Metastasis: Primary vs. Relapsed Tumors.
   Anticancer Res. 2025;45:1807-1812.
   PubMed     Abstract available
   
   
   
5. TSUKAMOTO YO, Ohtsuka T, Yamauchi Y, Mun M, et al
   Efficacy and Prognostic Factors of Surgical Resection for Pulmonary Metastases From Ovarian Cancer.
   Anticancer Res. 2025;45:2071-2078.
   PubMed     Abstract available
   
   
   April 2025
6. AMPIL F, Previgliano C, Heath K, Bozeman A, et al
   Does Aggressive Versus Less Aggressive Non-operative Treatment of Large and Very Large (>/=7 cm) Lung Cancers Matter?
   Anticancer Res. 2025;45:1593-1598.
   PubMed     Abstract available
   
   
   
7. MATSUDA H, Ikeda J, Ogasawara-Nosoko M, Endo M, et al
   Contrasting Role of COMMD5 in Renal Cell Carcinoma: Tumor Suppression and Metastatic Enhancement.
   Anticancer Res. 2025;45:1373-1385.
   PubMed     Abstract available
   
   
   
8. FUTAWATARI N, Fukuyama T, Akimoto Y, Maehara J, et al
   Association Between Kita-kyushu Lung Cancer Antigen-1 Expression in Gastric Cancer and Helicobacter pylori-infection Status.
   Anticancer Res. 2025;45:1599-1606.
   PubMed     Abstract available
   
   
   
9. ZHOU Y, Khawkhiaw K, Thithuan K, Saengboonmee C, et al
   Activation of the gamma-Aminobutyric Acid Receptor Type B Suppresses the Proliferation of Lung Adenocarcinoma Cells.
   Anticancer Res. 2025;45:1513-1523.
   PubMed     Abstract available
   
   
   
10. TANIGUCHI Y, Tamiya A, Kamiyama Y, Sumitani H, et al
    Real-world Data of the Lung Cancer Compact Panel in Non-small Cell Lung Cancer Using Tissue Samples.
    Anticancer Res. 2025;45:1607-1615.
    PubMed     Abstract available
    
    
    March 2025
11. TONE M, Isono T, Yamamoto Y, Takeda Y, et al
    Peripheral CD4(+) T Cells Predict T Cell Immunity in Lung Tissues of Non-small Cell Lung Cancer Patients.
    Anticancer Res. 2025;45:909-920.
    PubMed     Abstract available
    
    
    
12. WATANABE H, Nakamura S, Imamura Y, Okado S, et al
    Impact of Postoperative Therapy on Survival Outcomes in Non-small Cell Lung Cancer Patients With Microscopic Residual Disease.
    Anticancer Res. 2025;45:1193-1204.
    PubMed     Abstract available
    
    
    
13. YUI M, Nakamura S, Koike Y, Hirota K, et al
    Efficacy of Molecular-targeted Agents in Vertebral Metastasis Management in Non-small Cell Lung Cancer.
    Anticancer Res. 2025;45:1105-1115.
    PubMed     Abstract available
    
    
    February 2025
14. MATSUKIDA A, Imai H, Shiono A, Ryuno Y, et al
    Efficacy and Safety of Amrubicin Monotherapy After Chemoradiotherapy in Patients With Relapsed Limited Disease Small-cell Lung Cancer.
    Anticancer Res. 2025;45:733-741.
    PubMed     Abstract available
    
    
    
15. TAN XT, Huang SW, Lin YC, Lin FY, et al
    A New PD-L1 Nanobody Enhances Cell Death in Lung Cancer In Vitro and In Vivo.
    Anticancer Res. 2025;45:535-547.
    PubMed     Abstract available
    
    
    
16. KOH YW, Han JH, Haam S, Lee HW, et al
    Immunosuppressive State May Lead to Brain Metastases in Lung Squamous Cell Carcinoma: Gene Expression and Immunohistochemical Analysis.
    Anticancer Res. 2025;45:525-534.
    PubMed     Abstract available
    
    
    
17. MOTOYAMA M, Shigefuku R, Tanaka N, Nishizawa M, et al
    Acyclic Retinoid Inhibits the EGFR/AKT Signaling Pathway and Cancels Cisplatin-resistant Cell Characteristics.
    Anticancer Res. 2025;45:433-443.
    PubMed     Abstract available
    
    
    January 2025
18. KAWAMURA H, Imaizumi T, Miyakawa T, Nakao E, et al
    Development of a Prognostic Model for Stage IV Colorectal Cancer Using Metastatic Patterns.
    Anticancer Res. 2025;45:341-350.
    PubMed     Abstract available
    
    
    
19. IMPROTA G, Vita G, Tartarone A, Calice G, et al
    EGFR Exon 19 Insertions: Do Patients Respond to Tyrosine Kinase Inhibitor Treatment?
    Anticancer Res. 2025;45:335-340.
    PubMed     Abstract available
    
    
    
20. YOSHIDA K, Watanabe K, Nishimura T, Ikushima H, et al
    Improvement in Survival in Patients With Advanced Non-small Cell Lung Cancer.
    Anticancer Res. 2025;45:295-305.
    PubMed     Abstract available
    
    
    
21. LEE JY, Kim JN, Cho SG
    Kisspeptin Retards Tumor Growth of Lewis Lung Carcinoma Cells Through p38 MAPK-mediated Senescence.
    Anticancer Res. 2025;45:113-122.
    PubMed     Abstract available
    
    
    
22. YAMAUCHI K, Komuta R, Tanabe H, Yokoyama M, et al
    Real-world Outcomes of Durvalumab Consolidation in Elderly Patients With Unresectable NSCLC Following CCRT With Daily Low-dose Carboplatin.
    Anticancer Res. 2025;45:369-378.
    PubMed     Abstract available
    
    
    December 2024
23. TSURUOKA K, Tamura Y, Shimazu Y, Arai M, et al
    Association Between PD-L1 Expression and Efficacy of Chemoimmunotherapy in Extensive-stage Small Cell Lung Cancer.
    Anticancer Res. 2024;44:5531-5539.
    PubMed     Abstract available
    
    
    
24. FUJIWARA M, Mimae T, Kushitani K, Tsubokawa N, et al
    Mitochondrial Metabolism as a Potential Novel Therapeutic Target for Lung Adenocarcinoma.
    Anticancer Res. 2024;44:5241-5252.
    PubMed     Abstract available
    
    
    
25. TANIGUCHI Y, Shigenobu T, Hayashi A, Hirahara A, et al
    Optimal Therapy for Postoperative Recurrence: Does Salvage Radiation Work for Locoregional Recurrence?
    Anticancer Res. 2024;44:5541-5549.
    PubMed     Abstract available
    
    
    
26. WEI L, Jiang Z, Chen S, Xia N, et al
    Pseudogene KRT17P3 Promotes NSCLC Progression Through Mir-338-3p/USP7/C-Myc.
    Anticancer Res. 2024;44:5405-5423.
    PubMed     Abstract available
    
    
    
27. DE MORAES FCA, Souza MEC, DA Silva ER, Kreuz M, et al
    Impact of ABCG2 rs2231142(421C>A) Variant on the Clinical Outcomes of Patients With EGFR-mutated Non-small Cell Lung Cancer Treated With Gefitinib: A Comprehensive Meta-analysis.
    Anticancer Res. 2024;44:5361-5370.
    PubMed     Abstract available
    
    
    
28. HAYASHI A, Kamio K, Miyanaga A, Yoshida K, et al
    Ivermectin Enhances Paclitaxel Efficacy by Overcoming Resistance Through Modulation of ABCB1 in Non-small Cell Lung Cancer.
    Anticancer Res. 2024;44:5271-5282.
    PubMed     Abstract available
    
    
    
29. CANON V, Lopez-Guerra JL, Arteagoitia A, Del Hoyo O, et al
    Impact of Radiation Dose on the Survival of Patients With Non-small Cell Lung Cancer Treated With Palliative Intent: Results of a Multicenter Prospective Study.
    Anticancer Res. 2024;44:5477-5484.
    PubMed     Abstract available
    
    
    
30. TEGENBOSCH C, Vekens K
    Recurrence Risk and Its Impact on Current Treatment Strategies in Early and Locally Advanced NSCLC.
    Anticancer Res. 2024;44:5495-5500.
    PubMed     Abstract available
    
    
    November 2024
31. SHOJI F, Minemura A, Kozuma Y, Nouno T, et al
    A Prospective Observational Study Analyzing the Diversity and Specific Composition of the Oral and Gut Microbiota in Lung Cancer Patients.
    Anticancer Res. 2024;44:5067-5080.
    PubMed     Abstract available
    
    
    
32. NASER S, Schulz M, Schuchart S, VON Hammerstein-Equord A, et al
    Metabolomic Profiling of Large Extracellular Vesicles in Patients Suffering from Small Cell Lung Cancer.
    Anticancer Res. 2024;44:4729-4735.
    PubMed     Abstract available
    
    
    
33. NAKASHIMA K, Umeda Y, Demura Y, Yamaoka K, et al
    Long-term Responders to Nanoparticle Albumin-bound Paclitaxel Following Immune Checkpoint Inhibitor in Non-small Cell Lung Cancer.
    Anticancer Res. 2024;44:5105-5111.
    PubMed     Abstract available
    
    
    
34. VEHLOW A, Lange I, Lagies S, Kammerer B, et al
    Cytotoxic and Radiosensitizing Effects of European and African Propolis in 3D Lung Carcinoma Cell Cultures.
    Anticancer Res. 2024;44:4801-4811.
    PubMed     Abstract available
    
    
    
35. KUO LK, Fu YK, Yeh CC, Lee CY, et al
    Combined Treatment of Caffeic Acid Phenethyl Ester With Docetaxel Inhibits Survival of Non-small-cell Lung Cancer Cells via Suppression of c-MYC.
    Anticancer Res. 2024;44:4915-4928.
    PubMed     Abstract available
    
    
    
36. SUNG KS, Han SJ, Lee J, Kwon M, et al
    Identification of Plasma Protein Biomarkers for Predicting Lung Cancer.
    Anticancer Res. 2024;44:5147-5155.
    PubMed     Abstract available
    
    
    
37. JEON M, Yoo S, Park S, Choi Y, et al
    Over-expression of Transmembrane Protein 158 Predicts Aggressive Tumor Behavior and Poor Prognosis in Lung Cancer.
    Anticancer Res. 2024;44:4885-4893.
    PubMed     Abstract available
    
    
    
38. NGUYEN TQ, Nguyen DH, Phan UTT, Tran PTT, et al
    Fenbendazole and Diisopropylamine Dichloroacetate Exert Synergistic Anti-cancer Effects by Inducing Apoptosis and Arresting the Cell Cycle in A549 Lung Cancer Cells.
    Anticancer Res. 2024;44:4761-4772.
    PubMed     Abstract available
    
    
    
39. SUZUKI Y, Maeno K, Kagawa Y, Sone K, et al
    Association of Plasma Nestin With Response to Immune Checkpoint Inhibitors Combined With Chemotherapy in Extensive-stage Small-cell Lung Cancer: A Pilot Study.
    Anticancer Res. 2024;44:5095-5104.
    PubMed     Abstract available
    
    
    October 2024
40. NATHANI A, Khan I, Tanimoto MH, Mejia JAA, et al
    Antitumor Potential of Guttiferone E Combined With Carboplatin Against Osimertinib-resistant H1975 Lung Cancer Through Apoptosis.
    Anticancer Res. 2024;44:4175-4188.
    PubMed     Abstract available
    
    
    
41. TSUKAGUCHI A, Tamiya A, Fukuda S, Iwahashi Y, et al
    Safety and Efficacy of Durvalumab After Chemoradiotherapy in Antinuclear Antibody-positive Patients With Non-small Cell Lung Cancer.
    Anticancer Res. 2024;44:4517-4524.
    PubMed     Abstract available
    
    
    
42. ASANO Y, Yamamoto N, Hayashi K, Takeuchi A, et al
    Serum Inflammatory Dynamics as Novel Biomarkers for Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer With Bone Metastases.
    Anticancer Res. 2024;44:4493-4503.
    PubMed     Abstract available
    
    
    
43. KIM HJ, Kim DY
    Potential Anti-tumor Properties of PDIA4 in Lung Adenocarcinoma.
    Anticancer Res. 2024;44:4309-4315.
    PubMed     Abstract available
    
    
    
44. CHOI YJ, Ramos SC, Sim HB, Han JY, et al
    Promising Approach for Optimizing In Vivo Fluorescence Imaging in a Tumor Mouse Model: Precision in Cancer Research.
    Anticancer Res. 2024;44:4347-4358.
    PubMed     Abstract available
    
    
    
45. KURIBAYASHI K, Hirano J
    True Benefits of Immune Checkpoint Inhibitors in the Treatment of Malignant Pleural Mesothelioma in Japan.
    Anticancer Res. 2024;44:4135-4145.
    PubMed     Abstract available
    
    
    
46. KWON M, Lim D, Park J, Gil W, et al
    MiR-140-3p Improves Sensitivity to Docetaxel by Suppressing PD-L1/ABCG2/MVP Expression in Lung Adenocarcinoma.
    Anticancer Res. 2024;44:4283-4299.
    PubMed     Abstract available
    
    
    
47. LIN PJ, Kuo YC, Hu PW, Chen WL, et al
    Magnolol Induces Apoptosis and Suppresses Immune Evasion in Non-small Cell Lung Cancer Xenograft Models.
    Anticancer Res. 2024;44:4327-4337.
    PubMed     Abstract available
    
    
    
48. KIM I, Choi SH, Lee SY, Yoo SS, et al
    PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC.
    Anticancer Res. 2024;44:4505-4516.
    PubMed     Abstract available
    
    
    September 2024
49. SONG HJ, Sharma S, Kim T, Kim YH, et al
    Macrophage-induced Expression of TonEBP/NFAT5 Is Associated With Gefitinib Resistance and Migration in PC-9 Cells.
    Anticancer Res. 2024;44:3867-3874.
    PubMed     Abstract available
    
    
    
50. CHEN HJ, Cheng WC, Chen CH, Tu CY, et al
    Efficacy of Respiration-controlled Radiotherapy Among Patients With Locally Advanced-stage Lung Cancer: A Population-based Study.
    Anticancer Res. 2024;44:4093-4100.
    PubMed     Abstract available
    
    
    
51. SAGIE N, Romanov E, Kezerle Y, Meirovitz A, et al
    Expression Analysis of SSTR 1, 2 and 3 in Small-cell Lung Cancer Patients as Targets for Future Peptide Receptor Radionuclide Therapy.
    Anticancer Res. 2024;44:3807-3812.
    PubMed     Abstract available
    
    
    
52. TAKEDA K, Kikuchi Y, Sawada YU, Kumamoto T, et al
    Simultaneously Detected Liver and Lung Metastases from Colorectal Carcinoma: A Potential Treatment Strategy.
    Anticancer Res. 2024;44:3945-3954.
    PubMed     Abstract available
    
    
    
53. HAYASHI K, Ishikawa H, Fujiwara K, Nakai M, et al
    Stereotactic Ablative Radiotherapy for Early-stage Lung Cancer in Patients With Left Ventricular Assist Device: A Case Series.
    Anticancer Res. 2024;44:4113-4117.
    PubMed     Abstract available
    
    
    August 2024
54. URAMOTO H, Motono N, Iijima Y, Nakajima Y, et al
    Long-term Outcomes of Salvage Surgery Versus Induction Therapy Followed by Surgical Resection for Advanced NSCLC: A Propensity Score-matched Analysis.
    Anticancer Res. 2024;44:3525-3531.
    PubMed     Abstract available
    
    
    
55. ARICO D, Macri P, Bambaci M, Leone G, et al
    Non-palpable Pulmonary Nodules and Uniportal-VATS: Radio-guided Localization (ROLL) Experience of a Lung Multidisciplinary Team.
    Anticancer Res. 2024;44:3507-3514.
    PubMed     Abstract available
    
    
    
56. IMAMURA Y, Kato T, Nomata Y, Okado S, et al
    Efficacy of Immune Checkpoint Inhibitors in Postoperative Recurrence of Wild-type EGFR Non-Small Cell Lung Cancer.
    Anticancer Res. 2024;44:3451-3461.
    PubMed     Abstract available
    
    
    
57. NOHIRA S, Kuramitsu S, Ohno M, Fujita M, et al
    Tertiary Lymphoid Structures in Brain Metastases of Lung Cancer: Prognostic Significance and Correlation With Clinical Outcomes.
    Anticancer Res. 2024;44:3615-3621.
    PubMed     Abstract available
    
    
    July 2024
58. OHGURI T, Morisaki T, Itamura H, Tani S, et al
    Prophylactic Effect of Clarithromycin on Radiation Pneumonitis in IMRT for Lung Cancer.
    Anticancer Res. 2024;44:2989-2995.
    PubMed     Abstract available
    
    
    
59. LUUKKAINEN MEK, Koivunen JP
    ALK Inhibitor and Chemotherapy Combinations in Models of ALK-Translocated NSCLC.
    Anticancer Res. 2024;44:2805-2813.
    PubMed     Abstract available
    
    
    
60. ZO S, Kim C, Lee HY, Park G, et al
    Comparative Analysis of Clinical Characteristics and Prognosis Between Primary Lung Cancers Identified as Screening Detected and Incidentally Detected Pulmonary Nodules.
    Anticancer Res. 2024;44:3163-3173.
    PubMed     Abstract available
    
    
    
61. IGATA F, Inoue H, Ikeda T, Nakao A, et al
    Comparison of Real-world Efficacy and Safety of Atezolizumab and Durvalumab in Combination With Chemotherapy for First-line Treatment of Extensive-stage Small-cell Lung Cancer.
    Anticancer Res. 2024;44:3175-3183.
    PubMed     Abstract available
    
    
    
62. EBI N, Inoue H, Igata F, Okuma R, et al
    Clinical Association Between Immune-related Adverse Events and Treatment Efficacy in Patients With Non-small-cell Lung Cancer Treated With Nivolumab-Ipilimumab-based Therapy.
    Anticancer Res. 2024;44:3087-3095.
    PubMed     Abstract available
    
    
    June 2024
63. SWITLIK W, Wyzewski Z, Gregorczyk-Zboroch K, Gietler M, et al
    Deciphering the Role of miR-30a-5p and DLGAP1 Gene in Non-small Cell Lung Cancer.
    Anticancer Res. 2024;44:2445-2451.
    PubMed     Abstract available
    
    
    
64. ANO S, Kikuchi N, Okauchi S, Numata T, et al
    Real Clinical Practice of Combined Atezolizumab Plus Chemotherapy in Patients With Small Cell Lung Cancer.
    Anticancer Res. 2024;44:2725-2730.
    PubMed     Abstract available
    
    
    
65. ENDO K, Tanaka H, Matsuo H, Onoda T, et al
    Adverse Event Profile of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel Combination Therapy Based on JADER.
    Anticancer Res. 2024;44:2653-2660.
    PubMed     Abstract available
    
    
    
66. SEO HR, Kim HJ, Ryu H, Song JY, et al
    Ionizing Radiation-treated NRF2-deficient Cancer Cells Promote Type I Interferon Signaling in Immune Cells.
    Anticancer Res. 2024;44:2577-2585.
    PubMed     Abstract available
    
    
    
67. PARK JS, Park HY, Choi Y
    Effect of Epidermal Growth Factor Receptor Mutation on Positron Emission Tomography/Computed Tomography in Lung Cancer.
    Anticancer Res. 2024;44:2681-2687.
    PubMed     Abstract available
    
    
    May 2024
68. SOLIS-ESTRADA J, Arredondo-Espinoza E, Pioquinto-Avila E, Gonzalez-Cruz AO, et al
    Design and Evaluation of a Humanized Anti-EGFR huscFv Antibody Fragment in Combination With Metformin in A549 Cells In Vitro.
    Anticancer Res. 2024;44:1955-1962.
    PubMed     Abstract available
    
    
    
69. CHEN LH, Tsai YF, Wu WT, Chiu KL, et al
    Association of Matrix Metalloproteinase-9 Genotypes With Lung Cancer Risk in Taiwan.
    Anticancer Res. 2024;44:1845-1852.
    PubMed     Abstract available
    
    
    
70. RADES D, Cremers F, Janssen S, Bartscht T, et al
    Associations Between Mean Lung Dose and Prevalence of Radiation Pneumonitis in Elderly Lung Cancer Patients.
    Anticancer Res. 2024;44:2073-2079.
    PubMed     Abstract available
    
    
    
71. CHOI YJ, Chung YH, Lee K, Jeong M, et al
    SH003 Enhances the Anti-cancer Effects of Dabrafenib on Lung Cancer Harboring BRAF G469A Mutation by Inhibiting the MAPK Signaling Pathway.
    Anticancer Res. 2024;44:1905-1913.
    PubMed     Abstract available
    
    
    
72. JI N, Lee Y, Lee SH, Kim HS, et al
    Diagnostic Value of Immunostaining for Thyroid Transcription Factor 1 (TTF1) and Paired Box 8 (PAX8) in Distinguishing Pulmonary Metastases of Mesonephric and Mesonephric-like Adenocarcinomas from Primary Lung Adenocarcinomas.
    Anticancer Res. 2024;44:2159-2170.
    PubMed     Abstract available
    
    
    
73. CHARPIDOU A, Mani M, Kokkotou E, Stournara L, et al
    Molecular Diagnostics and Treatment Patterns in Metastatic Non-small Cell Lung Cancer Patients: Real World Evidence from Greece: LACHESIS Study.
    Anticancer Res. 2024;44:2063-2072.
    PubMed     Abstract available
    
    
    
74. KOH YW, Han JH, Haam S, Lee HW, et al
    Prediction of Responsiveness to PD-L1/PD-1 Inhibitors Using miRNA Profiles Associated With PD-L1 Expression in Lung Adenocarcinoma and Squamous Cell Carcinoma.
    Anticancer Res. 2024;44:2081-2089.
    PubMed     Abstract available
    
    
    April 2024
75. MAEZAWA Y, Taguchi M, Kawakami T, Inui T, et al
    Patient Age and EGFR-positive Non-small Cell Lung Cancer: A Multicenter Retrospective Study.
    Anticancer Res. 2024;44:1751-1757.
    PubMed     Abstract available
    
    
    
76. CHIU KL, Wang SC, Li CH, Shen TC, et al
    The Contribution of Double-strand Break Repair Radiation Sensitive Protein 51 Genotypes to Lung Cancer in Taiwan.
    Anticancer Res. 2024;44:1409-1416.
    PubMed     Abstract available
    
    
    
77. HASHIMOTO K, Kaira K, Imai H, Miura YU, et al
    Metabolic Tumor Volume as Significant Predictor for Chemotherapy Containing PD-L1 Blocker in Extensive Stage Small Cell Lung Cancer.
    Anticancer Res. 2024;44:1541-1551.
    PubMed     Abstract available
    
    
    March 2024
78. INOMATA M, Minatoyama S, Takata N, Hayashi K, et al
    Immune Checkpoint Inhibitor Therapy for Patients With Non-small Cell Lung Cancer Ineligible for Platinum Doublet Chemotherapy.
    Anticancer Res. 2024;44:1241-1245.
    PubMed     Abstract available
    
    
    
79. KINOSHITA H, Kinoshita S, Kamoda H, Hagiwara Y, et al
    Combined Auranofin and Celecoxib Suppresses the Local Progression and Pulmonary Metastases of Osteosarcoma In Vivo.
    Anticancer Res. 2024;44:1045-1049.
    PubMed     Abstract available
    
    
    
80. YOSHIDA C, Kadota K, Ibuki E, Ishikawa R, et al
    Siglec10 Expression on Tumor-associated Macrophages Is an Independent Prognostic Factor in Stage I Lung Adenocarcinoma.
    Anticancer Res. 2024;44:1289-1297.
    PubMed     Abstract available
    
    
    February 2024
81. NATSUME K, Ye J, Mukai Y, Yamakawa K, et al
    Discrepancies Between Morphological and Immunohistochemical Classifications Are Associated With Prognoses and Subtypes of Lung Cancer.
    Anticancer Res. 2024;44:711-722.
    PubMed     Abstract available
    
    
    
82. TRINH JQ, Xiong Y, Smith LM, Abughanimeh O, et al
    Durvalumab Outcomes in Stage III Non-small Cell Lung Cancer: A Single-institution Study.
    Anticancer Res. 2024;44:605-612.
    PubMed     Abstract available
    
    
    
83. KANASAKI H, Ozawa Y, Nakamura N, Nagasaki K, et al
    Upfront Multiplex Gene Test Helps Prolong Survival in Advanced Non-small Cell Lung Cancer.
    Anticancer Res. 2024;44:723-730.
    PubMed     Abstract available
    
    
    
84. KURIHARA S, Nakamura R, Yoneyama S, Takase S, et al
    Prognostic Impact of Preoperative Assessment of Muscle Mass and Strength in Surgically Resected Lung Cancer.
    Anticancer Res. 2024;44:767-779.
    PubMed     Abstract available
    
    
    
85. NAKAO M, Kinoshita R, Kuriyama M, Kiyotoshi H, et al
    Serum CYFRA 21-1 Level as a Prognostic Marker for Extensive Disease Small Cell Lung Cancer.
    Anticancer Res. 2024;44:845-851.
    PubMed     Abstract available
    
    
    
86. CHECK JH, Check DL, DO TP, Srivastava M, et al
    Significant Palliative Benefits Following Therapy With Mifepristone for Advanced Treatment Resistant Small Cell Lung Cancer.
    Anticancer Res. 2024;44:659-664.
    PubMed     Abstract available
    
    
    
87. MATSUMOTO T, Toya R, Shimohigashi Y, Yamaguchi K, et al
    Influence of Respiratory Motion on Dose Distribution in Gastric Mucosa-associated Lymphoid Tissue Lymphoma Radiotherapy.
    Anticancer Res. 2024;44:687-694.
    PubMed     Abstract available
    
    
    
88. BARUT Z, Akdeniz FT, Isbir T
    Investigation of Mirna-223-3p Expression in Non-small Cell Lung Cancers.
    Anticancer Res. 2024;44:585-591.
    PubMed     Abstract available
    
    
    
89. HONG JM, Jeong BK, Han D, Kim K, et al
    CCR10-mediated Enhancement of T Cell Trafficking for Improved Tumor Immunotherapy.
    Anticancer Res. 2024;44:521-532.
    PubMed     Abstract available
    
    
    January 2024
90. NIEDER C, Aanes SG, Dalhaug A, Haukland EC, et al
    Sex Differences in Presentation, Treatment, and Survival in Patients Receiving Palliative (Chemo)Radiotherapy for Non-Small Cell Lung Cancer.
    Anticancer Res. 2024;44:301-305.
    PubMed     Abstract available
    
    
    
91. CHEN PM, Huang YH, Chen HH, Chu PY, et al
    Catalase Expression Is an Independent Prognostic Marker in Lung Adenocarcinoma.
    Anticancer Res. 2024;44:287-300.
    PubMed     Abstract available
    
    
    
92. TATE MK, Hernandez M, Chang JY, Lin SH, et al
    Metformin in Conjunction With Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer: Long-term Results of a Prospective Phase II Clinical Trial.
    Anticancer Res. 2024;44:133-137.
    PubMed     Abstract available
    
    
    
93. MOSER SS, Apter L, Solomon J, Chodick G, et al
    Time on Treatment and Survival Outcomes for Patients Treated With First-line Osimertinib vs. Other Tyrosine Kinase Inhibitors, for EGFR Mutation-positive Metastatic Non-small Cell Lung Cancer: Real-world Experience Data.
    Anticancer Res. 2024;44:257-265.
    PubMed     Abstract available
    
    
    December 2023
94. AGOLLI L, Eroglu Z, Nicosia L, Habermehl D, et al
    Dosimetric Parameters After VMAT Adaptive Radiotherapy in Patients With Locally Advanced NSCLC Undergoing 4DCT.
    Anticancer Res. 2023;43:5573-5582.
    PubMed     Abstract available
    
    
    
95. LEE HH, Hsieh CC, Chang CC, Liao WT, et al
    YTHDF3 Modulates EGFR/ATK/ERK/p21 Signaling Axis to Promote Cancer Progression and Osimertinib Resistance of Glioblastoma Cells.
    Anticancer Res. 2023;43:5485-5498.
    PubMed     Abstract available
    
    
    
96. KIMURA N, Kadota K, Ibuki E, Ishikawa R, et al
    (Pro)renin Receptor Down-regulation Is Associated With a Higher Risk of Recurrence in Lung Adenocarcinoma.
    Anticancer Res. 2023;43:5671-5680.
    PubMed     Abstract available
    
    
    
97. TONG X, Zhang R, Sun R, Yang W, et al
    Disclosing Potential Therapeutic Targets Associated With Osimertinib Resistance in the Non-small Cell Lung Cancer Cell Line H1975.
    Anticancer Res. 2023;43:5459-5474.
    PubMed     Abstract available
    
    
    
98. ENDO I, Amatya VJ, Kushitani K, Nakagiri T, et al
    Long Non-coding RNA LINC00152 Requires EZH2 to Promote Mesothelioma Cell Proliferation, Migration, and Invasion.
    Anticancer Res. 2023;43:5367-5376.
    PubMed     Abstract available
    
    
    
99. LIU B, Pu ZY, Wang L, Fang J, et al
    Inhibiting miR-33b-5p Enhances Chemoresistance in Lung Adenocarcinoma by Targeting YWHAH to Regulate Epithelial-mesenchymal Transition.
    Anticancer Res. 2023;43:5447-5458.
    PubMed     Abstract available
    
    
    
100. LIN HW, Shih TW, Amanna A, Chang MS, et al
     PHRF1 Promotes Cell Invasion by Modulating SOX4 Expression in Colorectal Cancer HCT116-p53(-/-) Cells.
     Anticancer Res. 2023;43:5437-5446.
     PubMed     Abstract available
     
     
     
101. ZHANG XW, Mohr J, Halama N, Koschny R, et al
     Analysis of an Unselected Patient Cohort With Advanced Colorectal Carcinoma from a Maximum Care Center.
     Anticancer Res. 2023;43:5589-5596.
     PubMed     Abstract available
     
     
     November 2023
102. ITO S, Tsurumi K, Shindo N, Soma S, et al
     Multi-gene Liquid Biopsy to Detect Resistance to First-line Osimertinib in Patients With EGFR-mutated Lung Adenocarcinoma.
     Anticancer Res. 2023;43:5031-5040.
     PubMed     Abstract available
     
     
     
103. SAKAI K, Kuramoto J, Takahashi T, Kawano Y, et al
     Impact of Locoregional Therapies for Brain Lesions on Survival in Patients With Non-small Cell Lung Cancer With Multiple Extrathoracic Metastases.
     Anticancer Res. 2023;43:5107-5114.
     PubMed     Abstract available
     
     
     
104. ITO A, Tarukawa T, Suzuki Y, Sakaguchi T, et al
     Clinicopathological and Molecular Characteristics Promoting PD-L1 Expression in Early-stage Lung Adenocarcinoma and Squamous Cell Carcinoma.
     Anticancer Res. 2023;43:5197-5204.
     PubMed     Abstract available
     
     
     
105. YANG T, Si Q, Liu M, DU R, et al
     Novel Biomarker miRNA-625-3p Promotes Cell Proliferation and Metastasis of Lung Adenocarcinoma by Targeting KLF9.
     Anticancer Res. 2023;43:4923-4935.
     PubMed     Abstract available
     
     
     
106. MATSUDO K, Takenaka T, Hashinokuchi A, Nagano T, et al
     Impact of Chronic Obstructive Pulmonary Disease on the Long-term Prognosis of Patients Undergoing Lobectomy for Non-small-cell Lung Cancer: A Propensity Score-matched Analysis.
     Anticancer Res. 2023;43:5215-5222.
     PubMed     Abstract available
     
     
     
107. ISOYAMA-SHIRAKAWA Y, Yoshitake T, Ninomiya K, Asai K, et al
     Combination of Clinical Factors and Radiomics Can Predict Local Recurrence and Metastasis After Stereotactic Body Radiotherapy for Non-small Cell Lung Cancer.
     Anticancer Res. 2023;43:5003-5013.
     PubMed     Abstract available
     
     
     October 2023
108. TAMURA T, Numata T, Yanai H, Nakamura R, et al
     Atezolizumab for EGFR-mutated Non-small Cell Lung Cancer Patients: An Observation Study in Ibaraki Group (ATTENTION-IBARAKI).
     Anticancer Res. 2023;43:4583-4591.
     PubMed     Abstract available
     
     
     
109. SAWABATA N, Morita K, Tatsumi S, Fujii T, et al
     A Novel Filtration Membrane for Clustered Circulating Tumor Cell Extraction: A Prospective Feasibility Study.
     Anticancer Res. 2023;43:4683-4690.
     PubMed     Abstract available
     
     
     
110. NAGAMINE H, Yashiro M, Yoshimoto N, Izumi M, et al
     RBM17 Expression Is Associated With the Efficacy of ICI Monotherapy in NSCLC With Low PD-L1 Expression.
     Anticancer Res. 2023;43:4663-4672.
     PubMed     Abstract available
     
     
     
111. ZHAO QI, Ren W, Gao S, Mu N, et al
     Immune Cell Infiltration and Clinical Significance of Angiogenesis-related Genes in Lung Adenocarcinoma.
     Anticancer Res. 2023;43:4473-4489.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.